Last Tuesay marked the official kick-off of the first TMC Netherlands BioBridge programme at CIC Rotterdam.
We are proud to see our portfolio companies ShanX Medtech BV and VivArt-X joining a cohort of 12 Dutch medtech companies preparing for their next steps into the U.S. healthcare market.
Over the coming months, the companies will work together with experts and peers to sharpen their U.S. market strategies, before connecting with the ecosystem of the Texas Medical Center in Houston, including hospitals, clinicians, entrepreneurs and investors.
Entering the U.S. market can be a major step for European medtech companies. Programmes like BioBridge can make that journey more focused by combining local expertise, access to the right networks and the opportunity to learn from other founders facing similar challenges.
We look forward to following ShanX, VivArt-X and the rest of the cohort on their journey to Houston.